US4327080A
(en)
|
1981-07-13 |
1982-04-27 |
E. R. Squibb & Sons, Inc. |
Novel Bendroflumethiazide formulations and method
|
US5002776A
(en)
|
1983-12-22 |
1991-03-26 |
Elan Corporation, Plc |
Controlled absorption diltiazem formulations
|
GB8608335D0
(en)
|
1986-04-04 |
1986-05-08 |
Pfizer Ltd |
Pharmaceutically acceptable salts
|
US4808413A
(en)
|
1987-04-28 |
1989-02-28 |
E. R. Squibb & Sons, Inc. |
Pharmaceutical compositions in the form of beadlets and method
|
US5049394A
(en)
|
1987-09-11 |
1991-09-17 |
E. R. Squibb & Sons, Inc. |
Pharmaceutical composition containing high drug load and method for preparing same
|
US5744166A
(en)
|
1989-02-25 |
1998-04-28 |
Danbiosyst Uk Limited |
Drug delivery compositions
|
US5212165A
(en)
|
1989-10-23 |
1993-05-18 |
E. R. Squibb & Sons, Inc. |
Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor
|
US5707644A
(en)
|
1989-11-04 |
1998-01-13 |
Danbiosyst Uk Limited |
Small particle compositions for intranasal drug delivery
|
US5270317A
(en)
|
1990-03-20 |
1993-12-14 |
Elf Sanofi |
N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
|
FR2665702B1
(fr)
|
1990-08-08 |
1994-02-25 |
Sanofi |
Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
|
PT97078B
(pt)
|
1990-03-20 |
1997-07-31 |
Sanofi Sa |
Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
|
FR2681067B1
(fr)
|
1991-09-10 |
1993-12-17 |
Elf Sanofi |
Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
|
FR2659967B1
(fr)
|
1990-03-20 |
1992-07-24 |
Sanofi Sa |
Derives d'imidazolinone n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
|
US5298497A
(en)
|
1990-05-15 |
1994-03-29 |
E. R. Squibb & Sons, Inc. |
Method for preventing onset of hypertension employing a cholesterol lowering drug
|
US5140012A
(en)
|
1990-05-31 |
1992-08-18 |
E. R. Squibb & Sons, Inc. |
Method for preventing onset of restenosis after angioplasty employing pravastatin
|
US5622985A
(en)
|
1990-06-11 |
1997-04-22 |
Bristol-Myers Squibb Company |
Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
|
US5137902A
(en)
|
1990-07-13 |
1992-08-11 |
E. I. Du Pont De Nemours And Company |
4-alkylimidazole derivatives and anti-hypertensive use thereof
|
US5089626A
(en)
|
1990-08-23 |
1992-02-18 |
Merck & Co., Inc. |
Process for preparing an angiotensin II antagonist
|
US5032578A
(en)
|
1990-09-17 |
1991-07-16 |
E. R. Squibb & Sons, Inc. |
Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
|
US5098889A
(en)
|
1990-09-17 |
1992-03-24 |
E. R. Squibb & Sons, Inc. |
Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
|
US6034114A
(en)
|
1990-12-14 |
2000-03-07 |
Smithkline Beecham Plc |
Medicament
|
WO1992010097A1
(en)
|
1990-12-14 |
1992-06-25 |
Smithkline Beecham Corporation |
Angiotensin ii receptor blocking compositions
|
US6025380A
(en)
|
1990-12-14 |
2000-02-15 |
Smithkline Beecham Plc |
Medicament
|
US20010016594A1
(en)
|
1990-12-14 |
2001-08-23 |
Smithkline Beecham P.L.C. |
Medicament
|
US6028091A
(en)
|
1990-12-14 |
2000-02-22 |
Smithkline Beecham Plc |
Medicament
|
US5472967A
(en)
|
1991-02-20 |
1995-12-05 |
Synthelabo |
4-pyrimidinone derivatives their preparation and their application in therapy
|
FR2673427B1
(fr)
|
1991-03-01 |
1993-06-18 |
Sanofi Elf |
Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
|
FR2677984B1
(fr)
|
1991-06-21 |
1994-02-25 |
Elf Sanofi |
Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
|
EP0521388B1
(de)
|
1991-07-01 |
1995-05-10 |
Gerhard Dr. Gergely |
Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung
|
AU2494792A
(en)
|
1991-08-19 |
1993-03-16 |
E.I. Du Pont De Nemours And Company |
Angiotensin ii receptor blocking imidazolinone derivatives
|
CZ36294A3
(en)
|
1991-08-19 |
1994-07-13 |
Du Pont |
Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
|
DE69331839T2
(de)
|
1992-01-29 |
2002-12-12 |
Takeda Chemical Industries Ltd |
Schnellösliche Tablette und ihre Herstellung
|
FR2688781B1
(fr)
|
1992-03-23 |
1994-07-01 |
Sanofi Elf |
Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
|
GB9208116D0
(en)
|
1992-04-13 |
1992-05-27 |
Ici Plc |
Therapeutic agents
|
US6673824B1
(en)
|
1992-05-06 |
2004-01-06 |
Bristol-Myers Squibb Co. |
Phenyl sulfonamide endothelin antagonists
|
EP0577023A3
(en)
|
1992-07-01 |
1996-12-18 |
Hoechst Ag |
Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
|
US5472711A
(en)
|
1992-07-30 |
1995-12-05 |
Edward Mendell Co., Inc. |
Agglomerated hydrophilic complexes with multi-phasic release characteristics
|
AU5449194A
(en)
|
1992-10-26 |
1994-05-24 |
Merck & Co., Inc. |
Combinations of angiotensin-ii receptor antagonists and diuretics
|
US5457112A
(en)
|
1992-12-14 |
1995-10-10 |
Synthelabo |
3-(6-quinolylmethyl)-4H-imidazol-4-one derivatives, their preparation and their application in therapy
|
WO1994018954A1
(en)
|
1993-02-22 |
1994-09-01 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of biologics and compositions useful therefor
|
US5914132A
(en)
|
1993-02-26 |
1999-06-22 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
EP0635263A3
(de)
|
1993-06-28 |
1995-09-27 |
American Cyanamid Co |
Angiotensin (AII)-antagonisten als Inhibitoren des Wachstums von Fettgewebe.
|
FR2708608B1
(fr)
|
1993-07-30 |
1995-10-27 |
Sanofi Sa |
Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
|
FR2708606B1
(fr)
|
1993-07-30 |
1995-10-27 |
Sanofi Sa |
Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
|
US5514670A
(en)
|
1993-08-13 |
1996-05-07 |
Pharmos Corporation |
Submicron emulsions for delivery of peptides
|
US5824696A
(en)
|
1993-09-01 |
1998-10-20 |
Smithkline Beecham Corporation |
Medicaments
|
US6174917B1
(en)
|
1993-09-08 |
2001-01-16 |
Pharmacy And Therapeutic Advisory Consultancy Ltd. |
Method of treating liver disease and like indications with vasodilating agents
|
US5464854A
(en)
|
1993-11-11 |
1995-11-07 |
Depadova; Anathony S. |
Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
|
JPH09510182A
(ja)
|
1993-11-17 |
1997-10-14 |
エルディーエス・テクノロジーズ・インコーポレーテッド |
カプセル封入されたドラッグデリバリー用透明液
|
US5536505A
(en)
|
1993-12-15 |
1996-07-16 |
Eastman Chemical Company |
Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
|
US5523095A
(en)
|
1993-12-15 |
1996-06-04 |
Eastman Chemical Company |
Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
|
DK0743852T3
(da)
|
1994-02-08 |
2005-10-17 |
Novartis Ag |
Behandling af glaukom med normalt tryk med valsartan
|
JP3414539B2
(ja)
|
1994-05-11 |
2003-06-09 |
有限会社ドット |
経鼻吸収用組成物
|
US6645463B1
(en)
|
1994-05-16 |
2003-11-11 |
The Board Of Regents Of The University Of Michigan |
Blood-pool selective carrier for lipophilic imaging agents
|
US5464633A
(en)
|
1994-05-24 |
1995-11-07 |
Jagotec Ag |
Pharmaceutical tablets releasing the active substance after a definite period of time
|
US5541209A
(en)
|
1994-08-22 |
1996-07-30 |
Bristol-Myers Squibb Company |
Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
|
US5612359A
(en)
|
1994-08-26 |
1997-03-18 |
Bristol-Myers Squibb Company |
Substituted biphenyl isoxazole sulfonamides
|
FR2725987B1
(fr)
|
1994-10-19 |
1997-01-10 |
Sanofi Sa |
Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US5780473A
(en)
|
1995-02-06 |
1998-07-14 |
Bristol-Myers Squibb Company |
Substituted biphenyl sulfonamide endothelin antagonists
|
CA2168066A1
(en)
|
1995-02-08 |
1996-08-09 |
James R. Powell |
Treatment of hypertension and congestive heart failure
|
FR2732223B1
(fr)
|
1995-03-30 |
1997-06-13 |
Sanofi Sa |
Composition pharmaceutique pour administration transdermique
|
US5731339A
(en)
*
|
1995-04-28 |
1998-03-24 |
Zonagen, Inc. |
Methods and formulations for modulating the human sexual response
|
US20020094346A1
(en)
|
1995-05-17 |
2002-07-18 |
M. D. Henry C. Lin |
Method and compositions for improving digestion and absorption in the small intestine
|
US5686106A
(en)
|
1995-05-17 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form for colonic delivery
|
SE9501881D0
(sv)
|
1995-05-19 |
1995-05-19 |
Astra Ab |
New pharmacological use of AII-receptor antagonists
|
US5645839A
(en)
|
1995-06-07 |
1997-07-08 |
Trustees Of Boston University |
Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
|
US5994348A
(en)
|
1995-06-07 |
1999-11-30 |
Sanofi |
Pharmaceutical compositions containing irbesartan
|
ES2167571T3
(es)
|
1995-06-07 |
2002-05-16 |
Searle & Co |
Terapia de combinacion de antagonista de aldosterona epoxi-esteroideo y antagonista de angiotensina ii para el tratamiento del fallo cardiaco congestivo.
|
TW442301B
(en)
|
1995-06-07 |
2001-06-23 |
Sanofi Synthelabo |
Pharmaceutical compositions containing irbesartan
|
FR2735365B1
(fr)
|
1995-06-14 |
1997-09-05 |
Sanofi Sa |
Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
|
SE9502219D0
(sv)
|
1995-06-19 |
1995-06-19 |
Astra Ab |
Novel medical use
|
US6057139A
(en)
*
|
1995-06-29 |
2000-05-02 |
Mcneil-Ppc, Inc. |
Preblend of microcrystalline cellulose and lactase for making tablets
|
US5846990A
(en)
|
1995-07-24 |
1998-12-08 |
Bristol-Myers Squibb Co. |
Substituted biphenyl isoxazole sulfonamides
|
FR2740136B1
(fr)
|
1995-10-24 |
1998-01-09 |
Sanofi Sa |
Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
|
FR2740686B1
(fr)
|
1995-11-03 |
1998-01-16 |
Sanofi Sa |
Formulation pharmaceutique lyophilisee stable
|
AU1791497A
(en)
|
1996-02-29 |
1997-09-16 |
Novartis Ag |
At1 receptor antagonist for the stimulation of apoptosis
|
FR2746013B1
(fr)
|
1996-03-18 |
1998-05-29 |
Sanofi Sa |
Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
|
US5939446A
(en)
|
1996-04-09 |
1999-08-17 |
Bristol-Myers Squibb Co. |
Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
|
AU714618B2
(en)
|
1996-07-15 |
2000-01-06 |
Sankyo Company Limited |
Medicinal composition
|
US5891469A
(en)
|
1997-04-02 |
1999-04-06 |
Pharmos Corporation |
Solid Coprecipitates for enhanced bioavailability of lipophilic substances
|
HRP970493A2
(en)
|
1996-09-23 |
1998-08-31 |
Wienman E. Phlips |
Oral delayed immediate release medical formulation and method for preparing the same
|
ATE314097T1
(de)
|
1996-10-28 |
2006-01-15 |
Amersham Health As |
Kontrastmittel
|
US6008221A
(en)
|
1996-11-06 |
1999-12-28 |
Bristol-Myers Squibb Company |
Method for treating Alzheimer's disease with folic acid
|
US6019988A
(en)
|
1996-11-18 |
2000-02-01 |
Bristol-Myers Squibb Company |
Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage
|
FR2757157B1
(fr)
|
1996-12-13 |
1999-12-31 |
Sanofi Sa |
Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
|
US6201002B1
(en)
|
1997-01-10 |
2001-03-13 |
Merck & Co., Inc. |
Method for reducing mortality with an angiotensin II antagonist
|
EP0855392A3
(de)
|
1997-01-22 |
2000-01-05 |
Hoechst Aktiengesellschaft |
Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
|
US5788987A
(en)
|
1997-01-29 |
1998-08-04 |
Poli Industria Chimica Spa |
Methods for treating early morning pathologies
|
TW536540B
(en)
|
1997-01-30 |
2003-06-11 |
Bristol Myers Squibb Co |
Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
|
WO1998033781A1
(en)
|
1997-01-30 |
1998-08-06 |
Bristol-Myers Squibb Company |
Method for preventing or treating low renin hypertension by administering an endothelin antagonist
|
US5846985A
(en)
|
1997-03-05 |
1998-12-08 |
Bristol-Myers Squibb Co. |
Substituted biphenyl isoxazole sulfonamides
|
TW580397B
(en)
|
1997-05-27 |
2004-03-21 |
Takeda Chemical Industries Ltd |
Solid preparation
|
DE19724696A1
(de)
|
1997-06-12 |
1998-12-24 |
Hexal Ag |
Pharmazeutische Zubereitung mit drei Pelletarten
|
CA2295177C
(en)
|
1997-06-13 |
2007-01-09 |
Medinova Medical Consulting Gmbh |
Drug targeting system, method of its preparation and its use
|
IT1292437B1
(it)
|
1997-06-30 |
1999-02-08 |
Zambon Spa |
Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti
|
HU218679B
(hu)
|
1997-07-25 |
2000-10-28 |
Sanofi-Synthelabo |
Eljárás imidazolonok előállítására és intermedierjeik
|
US20010044584A1
(en)
|
1997-08-28 |
2001-11-22 |
Kensey Kenneth R. |
In vivo delivery methods and compositions
|
GT199800126A
(es)
|
1997-08-29 |
2000-01-29 |
|
Terapia de combinacion.
|
NL1006903C2
(nl)
*
|
1997-09-01 |
1999-03-04 |
Johannes Gerardus Van Gemert |
Werkwijze voor het verdichten van vormzand.
|
EP0942780B1
(de)
|
1997-09-09 |
2003-07-30 |
Select Release, L.C. |
Beschichtete teilchen, methode zu ihrer herstellung und verwendung
|
US6248358B1
(en)
|
1998-08-25 |
2001-06-19 |
Columbia Laboratories, Inc. |
Bioadhesive progressive hydration tablets and methods of making and using the same
|
US20030077229A1
(en)
|
1997-10-01 |
2003-04-24 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
|
DE69830069T3
(de)
|
1997-10-17 |
2012-02-09 |
Ark Therapeutics Ltd. |
Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel
|
DE19750529A1
(de)
|
1997-11-14 |
1999-05-20 |
Basf Ag |
Neue heterocyclisch substituierte alpha-Hydroxycarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
|
JPH11137208A
(ja)
|
1997-11-14 |
1999-05-25 |
Nikken Chem Co Ltd |
口腔内速溶性固形物及びその製造方法
|
CN100379407C
(zh)
*
|
1997-12-19 |
2008-04-09 |
史密丝克莱恩比彻姆公司 |
生产咀嚼分散片的方法
|
US6162922A
(en)
|
1998-01-30 |
2000-12-19 |
Bristol-Myers Squibb Co. |
Method for preparing N-substituted heterocyclic derivatives using a phase-transfer catalyst
|
HRP980532B1
(en)
|
1998-10-02 |
2005-06-30 |
Pliva |
Novel crystalline torasemide modification
|
AU747110B2
(en)
|
1998-02-25 |
2002-05-09 |
Merck & Co., Inc. |
Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist
|
ATE258430T1
(de)
|
1998-03-04 |
2004-02-15 |
Takeda Chemical Industries Ltd |
Zubereitung mit verzögerter wirkstoffabgabe für aii antagonisten, ihre herstellung und verwendung
|
FR2775598A1
(fr)
|
1998-03-06 |
1999-09-10 |
Sanofi Sa |
Compositions pharmaceutiques contenant en association un antagoniste selectif des recepteurs v1a de l'arginine-vasopressine et un antagoniste selectif des recepteur v2 de l'arginine-vasopressine
|
US6284363B1
(en)
|
1998-03-23 |
2001-09-04 |
Fuji Polymer Industries Co., Ltd. |
Electromagnetic wave absorbing thermoconductive silicone gel molded sheet and method for producing the same
|
US20040062802A1
(en)
|
1998-04-02 |
2004-04-01 |
Hermelin Victor M. |
Maximizing effectiveness of substances used to improve health and well being
|
FR2778103A1
(fr)
|
1998-04-29 |
1999-11-05 |
Sanofi Sa |
Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii
|
AU766831B2
(en)
|
1998-05-11 |
2003-10-23 |
Takeda Pharmaceutical Company Limited |
Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
|
AU750122C
(en)
|
1998-06-17 |
2003-02-27 |
Bristol-Myers Squibb Company |
Preventing cerebral infarction through administration of ADP-receptor antiplatelet and antihypertensive drugs in combination
|
IT1301759B1
(it)
|
1998-06-19 |
2000-07-07 |
Nicox Sa |
Sali nitrati di farmaci antiipertensivi
|
FR2780403B3
(fr)
*
|
1998-06-24 |
2000-07-21 |
Sanofi Sa |
Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
|
US6638937B2
(en)
|
1998-07-06 |
2003-10-28 |
Bristol-Myers Squibb Co. |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
FR2780890B3
(fr)
|
1998-07-10 |
2000-09-01 |
Sanofi Sa |
Utilisation d'une composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et l'indomethacine pour le traitement des glomerulonephrites chroniques
|
TW585786B
(en)
|
1998-07-28 |
2004-05-01 |
Takeda Chemical Industries Ltd |
Lansoprazole-containing rapidly disintegrable solid pharmaceutical composition
|
AU5403499A
(en)
|
1998-08-26 |
2000-03-21 |
Queen's University At Kingston |
Methods for remodeling neuronal and cardiovascular pathways
|
US6489307B1
(en)
|
1998-09-14 |
2002-12-03 |
University Of Florida |
Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
|
FR2783422A1
(fr)
|
1998-09-21 |
2000-03-24 |
Sanofi Sa |
Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
|
US6531152B1
(en)
|
1998-09-30 |
2003-03-11 |
Dexcel Pharma Technologies Ltd. |
Immediate release gastrointestinal drug delivery system
|
US7815937B2
(en)
|
1998-10-27 |
2010-10-19 |
Biovail Laboratories International Srl |
Quick dissolve compositions and tablets based thereon
|
US6596747B2
(en)
|
1998-10-29 |
2003-07-22 |
Bristol-Myers Squibb Company |
Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
|
US20040141925A1
(en)
|
1998-11-12 |
2004-07-22 |
Elan Pharma International Ltd. |
Novel triamcinolone compositions
|
CA2350706A1
(en)
|
1998-11-13 |
2000-05-25 |
Elan Pharma International Limited |
Drug delivery systems and methods
|
TNSN99224A1
(fr)
|
1998-12-01 |
2005-11-10 |
Inst For Pharm Discovery Inc |
Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
|
FR2787330A1
(fr)
|
1998-12-18 |
2000-06-23 |
Sanofi Sa |
Composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et un immunosuppresseur pour la prevention ou le traitement des complications vasculaires du rejet de greffe
|
KR100349597B1
(ko)
|
1999-01-12 |
2002-08-22 |
삼성전자 주식회사 |
광도파로 소자 및 그 제조방법
|
US20030104048A1
(en)
|
1999-02-26 |
2003-06-05 |
Lipocine, Inc. |
Pharmaceutical dosage forms for highly hydrophilic materials
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
US7374779B2
(en)
|
1999-02-26 |
2008-05-20 |
Lipocine, Inc. |
Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
EP1169322B8
(de)
|
1999-03-08 |
2006-09-13 |
Medicure Inc. |
Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel
|
JP3695978B2
(ja)
|
1999-03-16 |
2005-09-14 |
三洋電機株式会社 |
渦巻状電極体を備えたアルカリ蓄電池
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
US6632451B2
(en)
|
1999-06-04 |
2003-10-14 |
Dexcel Pharma Technologies Ltd. |
Delayed total release two pulse gastrointestinal drug delivery system
|
US6387894B1
(en)
|
1999-06-11 |
2002-05-14 |
Pfizer Inc. |
Use of CRF antagonists and renin-angiotensin system inhibitors
|
KR20020013936A
(ko)
|
1999-06-25 |
2002-02-21 |
추후제출 |
치환된 페녹시아세트산
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
US20030235595A1
(en)
|
1999-06-30 |
2003-12-25 |
Feng-Jing Chen |
Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
|
SE9902597D0
(sv)
|
1999-07-06 |
1999-07-06 |
Astra Ab |
New use
|
US6677356B1
(en)
|
1999-08-24 |
2004-01-13 |
Medicure International Inc. |
Treatment of cardiovascular and related pathologies
|
US6432989B1
(en)
|
1999-08-27 |
2002-08-13 |
Pfizer Inc |
Use of CRF antagonists to treat circadian rhythm disorders
|
US20030225124A1
(en)
|
1999-08-31 |
2003-12-04 |
Spiridon Spireas |
Stable formulations of ACE inhibitors, and methods for preparation thereof
|
US6555551B1
(en)
|
1999-08-31 |
2003-04-29 |
Mutual Pharmaceutical Co., Inc. |
Stable formulations of ACE inhibitors, and methods for preparation thereof
|
WO2001017528A1
(en)
|
1999-09-08 |
2001-03-15 |
Nitromed, Inc. |
Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
|
US6414002B1
(en)
|
1999-09-22 |
2002-07-02 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
|
US6515117B2
(en)
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
PH12000002657B1
(en)
|
1999-10-12 |
2006-02-21 |
Bristol Myers Squibb Co |
C-aryl glucoside SGLT2 inhibitors
|
US6720001B2
(en)
|
1999-10-18 |
2004-04-13 |
Lipocine, Inc. |
Emulsion compositions for polyfunctional active ingredients
|
AU8026200A
(en)
|
1999-10-19 |
2001-04-30 |
Board Of Regents, The University Of Texas System |
Treatment of heart disease with cox-2 inhibitors
|
EP1093814A1
(de)
|
1999-10-22 |
2001-04-25 |
Boehringer Ingelheim Pharma KG |
Verwendung von Dipyridamole oder Mopidamol zur Herstellung eines Medikaments für die Behandlung und Vorbeugung von fibrinabhängigen Mikrozirkulationstörungen
|
US6264981B1
(en)
|
1999-10-27 |
2001-07-24 |
Anesta Corporation |
Oral transmucosal drug dosage using solid solution
|
US7537785B2
(en)
|
1999-10-29 |
2009-05-26 |
Nitromed, Inc. |
Composition for treating vascular diseases characterized by nitric oxide insufficiency
|
WO2001035961A1
(en)
|
1999-10-29 |
2001-05-25 |
Nitromed, Inc. |
Methods of treating vascular diseases characterized by nitric oxide insufficiency
|
US7235237B2
(en)
|
1999-10-29 |
2007-06-26 |
Nitromed, Inc. |
Methods of treating vascular diseases characterized by nitric oxide insufficiency
|
US20030113330A1
(en)
|
1999-11-08 |
2003-06-19 |
Uhal Bruce D. |
Methods for treating pulmonary fibrosis
|
US20030180352A1
(en)
|
1999-11-23 |
2003-09-25 |
Patel Mahesh V. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
IL133196A0
(en)
|
1999-11-29 |
2001-03-19 |
Yissum Res Dev Co |
Gastroretentive controlled release pharmaceutical dosage forms
|
MY125533A
(en)
|
1999-12-06 |
2006-08-30 |
Bristol Myers Squibb Co |
Heterocyclic dihydropyrimidine compounds
|
US20020068740A1
(en)
|
1999-12-07 |
2002-06-06 |
Mylari Banavara L. |
Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
|
FR2803525B1
(fr)
|
2000-01-06 |
2002-05-03 |
Sod Conseils Rech Applic |
Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
|
CA2396596A1
(en)
|
2000-01-28 |
2001-08-02 |
Bristol-Myers Squibb Company |
Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
|
US6570013B2
(en)
|
2000-02-16 |
2003-05-27 |
Pfizer Inc |
Salts of zopolrestat
|
PL356422A1
(en)
|
2000-02-18 |
2004-06-28 |
Takeda Chemical Industries, Ltd. |
Tnf-alpha inhibitors
|
US20030068374A1
(en)
|
2000-02-21 |
2003-04-10 |
Shigeru Kamei |
Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
|
US20030152636A1
(en)
|
2000-02-23 |
2003-08-14 |
Nanopharm Ag |
Method of treating cancer
|
DE60133323T2
(de)
|
2000-02-29 |
2009-03-05 |
Medicure International Inc. |
Cardioprotektive Phosphonate
|
AU2001238718A1
(en)
|
2000-03-02 |
2001-09-12 |
The Institutes For Pharmaceutical Discovery, Llc |
Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
|
CZ20023121A3
(cs)
|
2000-03-17 |
2003-05-14 |
Ajinomoto Co., Inc. |
Farmaceutické prostředky pro léčení diabetických komplikací a neuropatie a jejich použití
|
US6436684B1
(en)
|
2000-03-27 |
2002-08-20 |
Applera Corporation |
Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
|
DE10014588A1
(de)
|
2000-03-27 |
2001-10-04 |
Basf Ag |
Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
|
EP1277730A4
(de)
|
2000-03-28 |
2005-03-16 |
|
Hemmer der neovaskularisation
|
CA2403555A1
(en)
|
2000-03-28 |
2001-10-04 |
Queen's University At Kingston |
Methods for effecting neuroprotection
|
DE10015479A1
(de)
|
2000-03-29 |
2001-10-11 |
Basf Ag |
Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
|
CA2405496A1
(en)
|
2000-04-03 |
2001-10-11 |
Richard A. Reeves |
Vasopeptidase inhibitors to treat isolated systolic hypertension
|
GB0008269D0
(en)
|
2000-04-05 |
2000-05-24 |
Astrazeneca Ab |
Combination chemotherapy
|
GB2361185A
(en)
|
2000-04-10 |
2001-10-17 |
Nicholas J Wald |
Pharmaceutical formulation for the prevention of cardiovascular disease
|
AU5340101A
(en)
|
2000-04-11 |
2001-10-23 |
Atherogenics Inc |
Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
|
WO2003030868A1
(en)
|
2001-10-09 |
2003-04-17 |
Bristol-Myers Squibb Company |
Flashmelt oral dosage formulation
|
US20030083342A1
(en)
|
2002-08-27 |
2003-05-01 |
Steele Ronald Edward |
Combination of organic compounds
|
US20040023840A1
(en)
|
2000-04-12 |
2004-02-05 |
Marc De Gasparo |
Combination of organic compounds
|
CA2311734C
(en)
|
2000-04-12 |
2011-03-08 |
Bristol-Myers Squibb Company |
Flash-melt oral dosage formulation
|
AR030557A1
(es)
|
2000-04-14 |
2003-08-27 |
Jagotec Ag |
Una tableta en multicapa de liberacion controlada y metodo de tratamiento
|
ATE389455T1
(de)
|
2000-05-10 |
2008-04-15 |
Jagotec Ag |
Zerkleinerung mittels mahlkörper
|
JP2004507456A
(ja)
|
2000-05-11 |
2004-03-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
|
AU2001256733A1
(en)
|
2000-05-16 |
2001-11-26 |
Takeda Chemical Industries Ltd. |
Melanin-concentrating hormone antagonist
|
US6911468B2
(en)
|
2000-05-22 |
2005-06-28 |
Takeda Chemical Industries, Ltd. |
Tyrosine phosphatase inhibitors
|
WO2001089519A1
(en)
|
2000-05-22 |
2001-11-29 |
Nitromed, Inc. |
Thromboxane inhibitors, compositions and methods of use related applications
|
US20020049155A1
(en)
|
2000-05-31 |
2002-04-25 |
Hogenkamp Henricus P.C. |
Cobalamin compounds useful as cardiovascular agents and as imaging agents
|
US20030212124A1
(en)
|
2001-05-30 |
2003-11-13 |
Kevorkian Robert C. |
Use of ace inhibitors for treatment of patients suffering from behavioral disorders
|
US20020044962A1
(en)
|
2000-06-06 |
2002-04-18 |
Cherukuri S. Rao |
Encapsulation products for controlled or extended release
|
US7678387B2
(en)
|
2000-06-06 |
2010-03-16 |
Capricorn Pharma, Inc. |
Drug delivery systems
|
US6544981B2
(en)
|
2000-06-09 |
2003-04-08 |
Bristol-Myers Squibb Company |
Lactam inhibitors of factor Xa and method
|
US20020013334A1
(en)
|
2000-06-15 |
2002-01-31 |
Robl Jeffrey A. |
HMG-CoA reductase inhibitors and method
|
US6627636B2
(en)
|
2000-06-15 |
2003-09-30 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US20020028826A1
(en)
|
2000-06-15 |
2002-03-07 |
Robl Jeffrey A. |
HMG-CoA reductase inhibitors and method
|
US6620821B2
(en)
|
2000-06-15 |
2003-09-16 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US6670355B2
(en)
|
2000-06-16 |
2003-12-30 |
Wyeth |
Method of treating cardiovascular disease
|
US20020013335A1
(en)
|
2000-06-16 |
2002-01-31 |
American Home Products Corporation |
Method of treating cardiovascular disease
|
DE10029201A1
(de)
|
2000-06-19 |
2001-12-20 |
Basf Ag |
Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
|
US6656966B2
(en)
|
2000-06-22 |
2003-12-02 |
Nitromed, Inc. |
Nitrosated and nitrosylated taxanes, compositions and methods of use
|
KR100798566B1
(ko)
|
2000-06-27 |
2008-01-28 |
안제스에무지 가부시키가이샤 |
혈관 신생요법용 의약조성물
|
US7799794B2
(en)
|
2000-06-28 |
2010-09-21 |
Merck Sharp & Dohme Corp. |
Treatment for cardiovascular disease
|
US20030114420A1
(en)
|
2000-06-28 |
2003-06-19 |
Salvati Mark E. |
Fused cyclic modulators of nuclear hormone receptor function
|
WO2002002081A1
(en)
|
2000-07-05 |
2002-01-10 |
Capricorn Pharma, Inc. |
Rapid-melt semi-solid compositions, methods of making same and methods of using same
|
US6375982B1
(en)
|
2000-07-05 |
2002-04-23 |
Capricorn Pharma, Inc. |
Rapid-melt semi-solid compositions, methods of making same and method of using same
|
DE60128912T9
(de)
|
2000-07-07 |
2008-06-26 |
Medicure International Inc. |
Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
|
KR100866820B1
(ko)
|
2000-07-13 |
2008-11-04 |
다케다 야쿠힌 고교 가부시키가이샤 |
지질 풍부 플라크 퇴축제
|
US6610716B2
(en)
|
2000-07-13 |
2003-08-26 |
Alteon Incorporated |
Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging
|
US20030176426A1
(en)
|
2000-07-13 |
2003-09-18 |
Alteon, Inc. |
Method for treating fibrotic diseases or other indications with imidazolium agents
|
AU2001280804A1
(en)
|
2000-07-27 |
2002-02-13 |
Eileen R. Blasi |
Aldosterone blocker therapy to prevent or treat inflammation-related disorders
|
US6511973B2
(en)
|
2000-08-02 |
2003-01-28 |
Bristol-Myers Squibb Co. |
Lactam inhibitors of FXa and method
|
GB0020691D0
(en)
|
2000-08-22 |
2000-10-11 |
Boehringer Ingelheim Pharma |
Pharmaceutical combination
|
US6664230B1
(en)
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
US7166578B2
(en)
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
AU2001280135A1
(en)
|
2000-08-25 |
2002-03-04 |
Takeda Chemical Industries Ltd. |
Fibrinogen lowering agents
|
US6521747B2
(en)
|
2000-08-28 |
2003-02-18 |
Genaissance Pharmaceuticals, Inc. |
Haplotypes of the AGTR1 gene
|
CA2420844A1
(en)
|
2000-08-30 |
2003-02-28 |
Sankyo Company, Limited |
Medicinal compositions for preventing or treating heart failure
|
DE60137943D1
(de)
|
2000-08-31 |
2009-04-23 |
Jagotec Ag |
Gemahlene partikel
|
US6576644B2
(en)
|
2000-09-06 |
2003-06-10 |
Bristol-Myers Squibb Co. |
Quinoline inhibitors of cGMP phosphodiesterase
|
US6632180B1
(en)
|
2000-09-07 |
2003-10-14 |
John H. Laragh |
Method for evaluating and treating hypertension
|
US6595926B1
(en)
|
2000-09-07 |
2003-07-22 |
John H. Laragh |
Method for evaluating and treating hypertension
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
US20020048599A1
(en)
|
2000-10-20 |
2002-04-25 |
Thomas H. Mueller |
Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation
|
CA2425280A1
(en)
|
2000-10-26 |
2002-05-02 |
Pfizer Products Inc. |
Pyrimidine-2,4,6-trione metalloproteinase inhibitors
|
US6841671B2
(en)
|
2000-10-26 |
2005-01-11 |
Pfizer Inc. |
Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
|
CA2428817C
(en)
|
2000-11-17 |
2010-06-01 |
Takeda Chemical Industries, Ltd. |
Copolyvidone-containing preparation
|
US6670380B2
(en)
|
2000-11-20 |
2003-12-30 |
Bristol-Myers Squibb Co. |
Pyridone inhibitors of fatty acid binding protein and method
|
JP4107831B2
(ja)
|
2000-11-21 |
2008-06-25 |
第一三共株式会社 |
医薬組成物
|
CA2430341A1
(en)
|
2000-11-28 |
2002-06-06 |
The University Of Chicago |
Genetically engineered herpes virus for the treatment of cardiovascular disease
|
US6673802B2
(en)
|
2000-12-01 |
2004-01-06 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
WO2002043807A2
(en)
|
2000-12-01 |
2002-06-06 |
Novartis Ag |
Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
|
CA2430934C
(en)
|
2000-12-01 |
2011-06-21 |
Takeda Chemical Industries, Ltd. |
A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
|
US20020137755A1
(en)
|
2000-12-04 |
2002-09-26 |
Bilodeau Mark T. |
Tyrosine kinase inhibitors
|
WO2002049630A2
(en)
|
2000-12-21 |
2002-06-27 |
Bristol-Myers Squibb Company |
Method for preventing or treating pain by administering an endothelin antagonist
|
DE60138768D1
(de)
|
2000-12-28 |
2009-07-02 |
Kissei Pharmaceutical |
Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
|
WO2002053161A1
(en)
|
2000-12-29 |
2002-07-11 |
Alteon, Inc. |
Method for treating fibrotic diseases or other indications
|
CA2433425A1
(en)
|
2000-12-29 |
2002-09-06 |
Alteon, Inc. |
Method for treating fibrotic diseases or other indications iiic
|
WO2002053101A2
(en)
|
2000-12-29 |
2002-07-11 |
Alteon, Inc. |
Method for treating fibrotic diseases or other indications
|
ITMI20010129A1
(it)
|
2001-01-25 |
2002-07-25 |
Pharmacia & Upjohn Spa |
Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
|
ATE348649T1
(de)
|
2001-01-26 |
2007-01-15 |
Schering Corp |
Kombinationen von einem hemmer der sterol- absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen
|
US20030053981A1
(en)
|
2001-01-26 |
2003-03-20 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
SK9502003A3
(en)
|
2001-01-26 |
2003-12-02 |
Schering Corp |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
EP1671650A1
(de)
|
2001-01-26 |
2006-06-21 |
Schering Corporation |
Kombinationen von einem Hemmer der Sterol-Absorption und Nicotinsäure zur Behandlung von kardiovaskulären Indikationen
|
MXPA03006724A
(es)
|
2001-01-26 |
2003-10-24 |
Schering Corp |
Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares.
|
EP1358178A2
(de)
|
2001-01-30 |
2003-11-05 |
Bristol-Myers Squibb Company |
Sulfonamidlactam-inhibitoren von faktor xa
|
TWI255817B
(en)
|
2001-02-14 |
2006-06-01 |
Kissei Pharmaceutical |
Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
|
FI114483B
(fi)
|
2001-02-20 |
2004-10-29 |
Jurilab Ltd Oy |
Menetelmä kohonneen verenpaineen riskin osoittamiseksi ja sen käytöt
|
US7087579B2
(en)
|
2001-02-26 |
2006-08-08 |
Kissei Pharmaceutical Co., Ltd. |
Glucopyranosyloxypyrazole derivatives and medicinal use thereof
|
JP4147111B2
(ja)
|
2001-02-27 |
2008-09-10 |
キッセイ薬品工業株式会社 |
グルコピラノシルオキシピラゾール誘導体およびその医薬用途
|
DE60204611T2
(de)
|
2001-02-28 |
2006-05-11 |
Pfizer Products Inc., Groton |
Sulfonyl-pyridazinon-derivate zur Verwendung als Aldose-reduktase-inhibitoren
|
US20030119010A1
(en)
|
2001-03-01 |
2003-06-26 |
University Of Queensland |
Polynucleotides and polypeptides linked to a disease or condition
|
EP1370211A4
(de)
|
2001-03-02 |
2005-02-09 |
Bristol Myers Squibb Co |
Gleichzeitige verabreichung eines melanocortin rezeptor-agonists und eines phosphodiesterase-hemmers zur behandlung von erkrankungen im zusammenhang mit zyklischer amp
|
JP2004532838A
(ja)
|
2001-03-02 |
2004-10-28 |
ブリストル−マイヤーズ スクイブ カンパニー |
メラノコルチン受容体のモデュレーターとして有用な化合物及びそれを含む製薬組成物
|
US6936590B2
(en)
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
US6642244B2
(en)
|
2001-03-16 |
2003-11-04 |
Bristol-Myers Squibb Co. |
Pyrazolopyridopyrimidine inhibitors of cGMP phosphodiesterase
|
EP1247809A3
(de)
|
2001-03-30 |
2003-12-17 |
Pfizer Products Inc. |
Triazin-Verbindungen und ihre Verwendung als Hemmer der Sorbit-Dehydrogenase
|
PL365294A1
(en)
|
2001-03-30 |
2004-12-27 |
Pfizer Products Inc. |
Pyridazinone aldose reductase inhibitors
|
ES2258141T3
(es)
|
2001-04-11 |
2006-08-16 |
Bristol-Myers Squibb Company |
Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
|
US20030004199A1
(en)
|
2001-04-12 |
2003-01-02 |
Isabelle Ounis |
Method for preventing or treating pulmonary inflammation by administering an endothelin antagonist
|
WO2002083074A2
(en)
|
2001-04-13 |
2002-10-24 |
Children's Hospital Medical Center |
Methods for the treatment of hepatic disorders
|
WO2002087503A2
(en)
|
2001-04-26 |
2002-11-07 |
Vanderbilt University |
Compositions and methods for treating colorectal polyps and cancer
|
EP1406608B1
(de)
|
2001-05-02 |
2009-07-29 |
Nitromed, Inc. |
Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
|
US20020168393A1
(en)
|
2001-05-08 |
2002-11-14 |
Ryota Sugimoto |
Implantable medical material and implantable medical device
|
US20030073705A1
(en)
|
2001-05-14 |
2003-04-17 |
Shahnaz Shahinfar |
Method of treatment
|
US6777443B2
(en)
|
2001-05-15 |
2004-08-17 |
Novartis Ag |
Dipeptide derivatives
|
US20030078190A1
(en)
|
2001-05-25 |
2003-04-24 |
Weinberg Marc S. |
Methods for tissue protection using highly effective inhibition of the renin-angiotensin system
|
US20030060451A1
(en)
|
2001-05-29 |
2003-03-27 |
Rajneesh Taneja |
Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
|
EP1406611A2
(de)
|
2001-05-30 |
2004-04-14 |
Alteon, Inc. |
Behandlungsmethode für fibrotische erkrankungen oder andere indikationen
|
US20030092736A1
(en)
|
2001-05-30 |
2003-05-15 |
Cheng Peter T. |
Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
|
EP1404339A4
(de)
|
2001-05-30 |
2004-08-25 |
Alteon Inc |
Verfahren zur behandlung fibrotischer erkrankungen oder anderer indikationen vi
|
US6967212B2
(en)
|
2001-05-30 |
2005-11-22 |
Bristol-Myers Squibb Company |
Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
|
US7105556B2
(en)
|
2001-05-30 |
2006-09-12 |
Bristol-Myers Squibb Company |
Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
|
US20040156903A1
(en)
|
2002-05-22 |
2004-08-12 |
Abrams Andrew L.. |
Metering and packaging of controlled release medication
|
AU2002320038B2
(en)
|
2001-06-18 |
2007-07-05 |
Noven Pharmaceuticals, Inc. |
Enhanced drug delivery in transdermal systems
|
EP1414461A4
(de)
|
2001-07-13 |
2005-10-26 |
Bristol Myers Squibb Co |
Pyrazinon-hemmer des fettsäurebindenden proteins und verfahren
|
US20030158090A1
(en)
|
2001-07-23 |
2003-08-21 |
Ulrik Pedersen-Bjergaard |
Renin-angiotensin system in diabetes mellitus
|
EP1414795A4
(de)
|
2001-07-31 |
2006-03-01 |
Bristol Myers Squibb Co |
Bicyclische modulatoren der funktion des androgenrezeptors
|
US6825208B2
(en)
|
2001-08-20 |
2004-11-30 |
Bristol-Myers Squibb Pharma Company |
Tetrahydroquinoline derivatives as antithrombotic agents
|
US20030124196A1
(en)
|
2001-08-22 |
2003-07-03 |
Susan Weinbach |
Pulsatile release compositions and methods for enhanced intestinal drug absorption
|
US20030083286A1
(en)
|
2001-08-22 |
2003-05-01 |
Ching-Leou Teng |
Bioadhesive compositions and methods for enhanced intestinal drug absorption
|
US6669955B2
(en)
|
2001-08-28 |
2003-12-30 |
Longwood Pharmaceutical Research, Inc. |
Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
|
DE60226615D1
(de)
|
2001-08-28 |
2008-06-26 |
Schering Corp |
|
US6576256B2
(en)
|
2001-08-28 |
2003-06-10 |
The Brigham And Women's Hospital, Inc. |
Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
|
US20030087843A1
(en)
|
2001-09-05 |
2003-05-08 |
Washburn William N. |
O-pyrazole glucoside SGLT2 inhibitors and method of use
|
US20030050620A1
(en)
|
2001-09-07 |
2003-03-13 |
Isa Odidi |
Combinatorial type controlled release drug delivery device
|
CA2460117A1
(en)
|
2001-09-11 |
2003-03-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Expression profiling in the intact human heart
|
US6638542B2
(en)
|
2001-09-20 |
2003-10-28 |
Nutricia N.V. |
Reducing appetite in mammals by administering procyanidin and hydroxycitric acid
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
US7053080B2
(en)
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
TWI331526B
(en)
|
2001-09-21 |
2010-10-11 |
Bristol Myers Squibb Pharma Co |
Lactam-containing compounds and derivatives thereof as factor xa inhibitors
|
US20030119808A1
(en)
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
US7019010B2
(en)
|
2001-09-27 |
2006-03-28 |
Novertis Ag |
Combinations
|
US20030114469A1
(en)
|
2001-09-27 |
2003-06-19 |
Cohen David Saul |
Combinations
|
EP1298223A3
(de)
|
2001-09-28 |
2003-07-23 |
Pfizer Products Inc. |
Methoden die mit der A-C Wiederholungs-Z-Sequenz stromaufwärts des Aldosereduktasegens in Zusammenhang stehen
|
US20030144198A1
(en)
|
2001-09-28 |
2003-07-31 |
Collins Douglas A. |
Coadministration of transport protein with conjugated cobalamin to deliver agents
|
US20030134810A1
(en)
|
2001-10-09 |
2003-07-17 |
Chris Springate |
Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
|
US6592901B2
(en)
|
2001-10-15 |
2003-07-15 |
Hercules Incorporated |
Highly compressible ethylcellulose for tableting
|
CA2463908A1
(en)
|
2001-10-18 |
2003-04-24 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US20030152622A1
(en)
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
FR2831446B1
(fr)
|
2001-10-26 |
2004-03-05 |
Sanofi Synthelabo |
Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
|
AU2916902A
(en)
|
2001-10-29 |
2003-05-01 |
Caritas St. Elizabeth's Medical Center Of Boston, Inc. |
Glycogen synthase kinase function in endothelial cells
|
US20030083614A1
(en)
|
2001-10-30 |
2003-05-01 |
Boehringer Ingelheim Pharma Kg |
Controlled release endoprosthetic device
|
US20030195205A1
(en)
|
2001-11-02 |
2003-10-16 |
Pfizer Inc. |
PDE9 inhibitors for treating cardiovascular disorders
|
WO2003040114A1
(en)
|
2001-11-06 |
2003-05-15 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
|
MXPA04004370A
(es)
|
2001-11-09 |
2004-08-11 |
Schering Corp |
Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
|
PE20030592A1
(es)
|
2001-11-13 |
2003-07-07 |
Schering Corp |
Antagonista de nk1
|
US7361671B2
(en)
|
2001-11-15 |
2008-04-22 |
The Institute For Pharmaceutical Discovery, Inc. |
Substituted heteroarylalkanoic acids
|
WO2003043624A1
(en)
|
2001-11-16 |
2003-05-30 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
US20030206978A1
(en)
|
2001-11-29 |
2003-11-06 |
Bob Sherwood |
Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
|
TW200303309A
(en)
|
2001-12-04 |
2003-09-01 |
Bristol Myers Squibb Co |
Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors
|
TW200302225A
(en)
|
2001-12-04 |
2003-08-01 |
Bristol Myers Squibb Co |
Substituted amino methyl factor Xa inhibitors
|
WO2003048081A2
(en)
|
2001-12-04 |
2003-06-12 |
Bristol-Myers Squibb Company |
Glycinamides as factor xa inhibitors
|
US6831102B2
(en)
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
WO2003050110A1
(en)
|
2001-12-10 |
2003-06-19 |
Dr. Reddy's Laboratories Ltd. |
Amorphous form of 2-n-butyl-3-( (2-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl) methyl) -1,3-diazaspiro (4,4') non-1-en-4-one
|
PE20030762A1
(es)
|
2001-12-18 |
2003-09-05 |
Schering Corp |
Compuestos heterociclicos como antagonistas nk1
|
ATE404544T1
(de)
|
2001-12-19 |
2008-08-15 |
Bristol Myers Squibb Co |
Kondensierte heterocyclische verbindungen und deren analoga; modulatoren der funktion von nukleären hormonrezeptoren
|
EP1463510A2
(de)
|
2001-12-20 |
2004-10-06 |
Bristol-Myers Squibb Company |
Verabreichung eines vasopeptidase-hemmers zur verringerung des pulsdrucks
|
ES2294197T3
(es)
|
2001-12-21 |
2008-04-01 |
Supernus Pharmaceuticals, Inc. |
Formulacion de capsula oral con estabilidad fisica aumentada.
|
JP2005516968A
(ja)
|
2001-12-29 |
2005-06-09 |
ノボ ノルディスク アクティーゼルスカブ |
Glp−1化合物と糖尿病後期合併症モジュレーターの組み合わせ使用
|
EP1478648B1
(de)
|
2002-02-01 |
2014-04-30 |
ARIAD Pharmaceuticals, Inc. |
Phosphorhaltige verbindungen und deren verwendungen
|
WO2003065997A2
(en)
|
2002-02-06 |
2003-08-14 |
Vicor Technologies, Inc. |
Anti-infarction molecules
|
US20030221207A1
(en)
|
2002-02-13 |
2003-11-27 |
Pharmacia Corporation, Global Patent Department |
Cardiac-specific 11beta hydroxysteroid dehydrogenase type 2 transgenic mice
|
WO2003070278A1
(en)
|
2002-02-19 |
2003-08-28 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
|
US6951869B2
(en)
|
2002-02-26 |
2005-10-04 |
Schlesinger Stephen L |
Use of leukotriene receptor antagonist for treatment of scarring
|
ATE303178T1
(de)
|
2002-02-27 |
2005-09-15 |
Pfizer Prod Inc |
Acc-hemmer
|
US20040116510A1
(en)
|
2002-03-05 |
2004-06-17 |
Nichtberger Steven A. |
Antihypertensive agent and cholesterol absorption inhibitor combination therapy
|
US20030215526A1
(en)
|
2002-03-08 |
2003-11-20 |
Scott Stofik |
Stable formulations of angiotensin converting enzyme (ACE) inhibitors
|
CN101143221A
(zh)
|
2002-03-15 |
2008-03-19 |
布赖汉姆妇女医院 |
适合治疗剂全身性递送的中央气道给药
|
JP2005531516A
(ja)
|
2002-03-18 |
2005-10-20 |
ファイザー・プロダクツ・インク |
選択的ep4受容体アゴニストによる治療方法
|
US20030199424A1
(en)
|
2002-03-20 |
2003-10-23 |
Smith Maree Therese |
Method of treatment and/or prophylaxis
|
JP2005530719A
(ja)
|
2002-03-29 |
2005-10-13 |
ニューロジェン コーポレーション |
病原性炎症要素を有する状態の治療のための組み合わせ療法
|
AU2003223491A1
(en)
|
2002-04-05 |
2003-10-27 |
Nitromed, Inc. |
Nitric oxide donors, compositions and methods of use
|
US6930085B2
(en)
|
2002-04-05 |
2005-08-16 |
The Regents Of The University Of California |
G-type peptides to ameliorate atherosclerosis
|
AU2003225102A1
(en)
|
2002-04-23 |
2003-11-10 |
Bristol-Myers Squibb Company |
Modified-release vasopeptidase inhibitor formulation, combinations and method
|
US20030203027A1
(en)
|
2002-04-26 |
2003-10-30 |
Ethicon, Inc. |
Coating technique for deposition of drug substance on a substrate
|
CA2480092A1
(en)
|
2002-04-26 |
2003-11-06 |
Pfizer Products Inc. |
N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
|
NI200300045A
(es)
|
2002-04-26 |
2005-07-08 |
Pfizer Prod Inc |
Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
|
BR0309556A
(pt)
|
2002-04-26 |
2005-02-09 |
Pfizer Prod Inc |
Inibidores de metaloproteinase pirimidina-2,4,6-triona
|
WO2003090755A1
(en)
|
2002-04-26 |
2003-11-06 |
Schering Aktiengesellschaft |
Treatment of hypertension in women receiving hormone replacement therapy
|
WO2003091259A1
(en)
|
2002-04-26 |
2003-11-06 |
Pfizer Products Inc. |
Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
|
US20030203019A1
(en)
|
2002-04-30 |
2003-10-30 |
Cornelius John Mark |
Coated conditioners for use in foods and pharmaceuticals
|
TW200307667A
(en)
|
2002-05-06 |
2003-12-16 |
Bristol Myers Squibb Co |
Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
|
US7276514B2
(en)
|
2002-05-15 |
2007-10-02 |
Charitable Leadership Foundation - Medical Technology Acceleration Program |
Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
|
AUPS236902A0
(en)
|
2002-05-16 |
2002-06-13 |
Northern Sydney Area Health Service |
Composition and method for treating hypertension
|
TW200407324A
(en)
|
2002-05-17 |
2004-05-16 |
Bristol Myers Squibb Co |
Bicyclic modulators of androgen receptor function
|
US7375138B2
(en)
|
2002-05-18 |
2008-05-20 |
Sanofi-Aventis Deutschland Gmbh |
Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them
|
US7057046B2
(en)
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
WO2003099206A2
(en)
|
2002-05-21 |
2003-12-04 |
Bristol-Myers Squibb Company |
Indole compounds useful as impdh inhibitors
|
US20030229007A1
(en)
|
2002-05-30 |
2003-12-11 |
Roberto Levi |
Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
|
ATE390425T1
(de)
|
2002-05-31 |
2008-04-15 |
Schering Corp |
Xanthin-phosphodiesterase-v-hemmer polymorphe
|
US20030233118A1
(en)
|
2002-06-13 |
2003-12-18 |
Hui John C. K. |
Method for treating congestive heart failure using external counterpulsation
|
US7157100B2
(en)
|
2002-06-04 |
2007-01-02 |
J.B. Chemicals & Pharmaceuticals Ltd. |
Pharmaceutical composition for controlled drug delivery system
|
US7049333B2
(en)
|
2002-06-04 |
2006-05-23 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
|
US7763278B2
(en)
|
2002-06-10 |
2010-07-27 |
Elan Pharma International Ltd. |
Nanoparticulate polycosanol formulations and novel polycosanol combinations
|
US20040009972A1
(en)
|
2002-06-17 |
2004-01-15 |
Ding Charles Z. |
Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
|
AU2003245614A1
(en)
|
2002-06-19 |
2004-01-06 |
Bristol-Myers Squibb Company |
Ureido-substituted aniline compounds useful as serine protease inhibitors
|
EP1382334A1
(de)
|
2002-07-11 |
2004-01-21 |
Université de Picardie Jules Verne |
Verwendung von Angiotensin II AT1-Rezeptorblockern, allein oder in Kombination mit Thiazide oder Angiotensin II zur Behandlung von Schlaganfall
|
US20040138306A1
(en)
|
2002-07-25 |
2004-07-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
AU2003279842A1
(en)
|
2002-10-04 |
2004-05-04 |
Microchips, Inc. |
Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
|
US20040106954A1
(en)
|
2002-11-15 |
2004-06-03 |
Whitehurst Todd K. |
Treatment of congestive heart failure
|
US7268157B2
(en)
|
2002-11-26 |
2007-09-11 |
Shenzhen Chipscreen Biosciences, Ltd. |
Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
|